← Unicycive Therapeutics, Inc. (UNCY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Unicycive Therapeutics, Inc. (UNCY)
Pharmaceutical Preparations · market cap $134M · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-11 (est.)
Earnings
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Unicycive Therapeutics (UNCY) is a micro-cap pharmaceutical company with 22 employees and a ~$139M market cap, focused on its single disclosed pipeline asset, Oxylanthanum Carbonate, currently in Phase 2 for chronic kidney disease (CKD) requiring chronic dialysis. The company carries $37.4M in cash, an 18-month runway, and no meaningful revenue, with cumulative net losses exceeding $120M over the past five reported years.
The catalyst path
- 2026-11-11 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Oxylanthanum Carbonate | Phase 2 | Chronic Kidney Disease Requiring Chronic Dialysis |
Price & technical context
3-month
-20.6%
6-month
-36.1%
12-month
+4.4%
52-wk range
$4.44–$8.56
vs 50-day MA
-11.2%
vs 200-day MA
-27.9%
Realized vol
83.5%
Max drawdown
-58.4%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for UNCY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.